PROPELLON THERAPEUTICS
Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and proper histone modification. The overexpression of WDR5 and resulting deregulation of epigenetic mechanisms are implicated in various cancers and correlated with poor patient survival. Established by FACIT, Propellon’s WDR5 inhibitor platform arises from discoveries, research and innovations originating from OICR.
PROPELLON THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2016-06-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Total Employee:
1+
Status:
Active
Total Funding:
3 M USD
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Parthenon Therapeutics
Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.
Spero Therapeutics
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections.
Current Employees Featured
Investors List
FACIT
FACIT investment in Seed Round - Propellon Therapeutics
Jed McCaleb
Jed McCaleb investment in Seed Round - Propellon Therapeutics
Fight Against Cancer Innovation Trust
Fight Against Cancer Innovation Trust investment in Seed Round - Propellon Therapeutics
Dan Schultz
Dan Schultz investment in Seed Round - Propellon Therapeutics
Rami Essaid
Rami Essaid investment in Seed Round - Propellon Therapeutics